Between the spring of 2023 and the summer of 2024, state Medicaid programs removed roughly twenty-five million Americans from the rolls in the process bureaucratically named the unwinding. The pandemic-era rule requiring continuous coverage had expired, and states resumed the annual renewal process they had suspended for three years. The most common reason for removal was not that the beneficiary was ineligible. It was that the paperwork did not come back.

Two years later, roughly nine million of those Americans have re-enrolled, most of them after a gap during which they were uninsured. Roughly four million remain uninsured. The rest, best available data suggests, transitioned to marketplace or employer coverage, in many cases at premiums they can afford only with subsidy structures that are themselves due to expire.

The clinical consequences of the gap are becoming visible in the data now, not in the aggregate mortality figures — those move slowly — but in the intermediate indicators that predict them. Diabetes-related emergency-department visits in the states with the highest procedural-disenrollment rates are up seventeen percent over 2022. Postpartum readmissions in the same states are up nine percent. Prescription abandonment for insulin, statins, and antihypertensives is up across the board.

None of this was surprising. The pattern was documented in the state-level unwinding pilots CMS ran in 2018. What was surprising was the political inertness of the entire episode. The largest coverage loss in the program's history was administered not by legislation but by a form letter that the state was not required to prove had been received. There was no vote. There was, in most states, not even a public hearing.

The design lessons are clear enough to fit on an index card. Renewals should be passive when the state already has the eligibility data. When they must be active, the state should be required to make contact by at least two channels and to document delivery. Procedural disenrollments should trigger an automatic ninety-day grace period rather than an immediate loss. None of these are novel ideas. All of them were on the table in 2022. None were adopted.

The unwinding is over as an administrative event. As a health story, and as a political story, it is only beginning. The states that did it well now have data that the states that did it poorly would rather not look at. Whether Congress or CMS forces that comparison into the open is the policy question of the next two years.